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A bout 10% of infants with Down syndrome (DS) are estimated to develop transient abnormal 
myelopoiesis (TAM),  which is characterized by an 
increased number of blasts in the peripheral blood at the 
time of birth [1].  In most infants,  TAM resolves 
spontaneously; however,  cytokine production and 
hyperviscosity due to increased blasts and sustained 
immunological dysfunction cause various pathological 
conditions,  and about 20-30% of these infants die due 
to cardiopulmonary or liver failure [2].  For example,  
liver failure is occasionally lethal,  and all patients with 
DS-TAM may develop liver disease,  irrespective of the 
absence or presence of symptoms; liver failure is also 
considered to be a risk factor for early death [3].  These 
conditions are estimated to start in utero and subse-
quently cause hydrops fetalis (HF),  which is strongly 
associated with a poor prognosis [4 , 5].  HF is a serious 
fetal condition defined as an abnormal accumulation of 
fluid in two or more fetal compartments,  and it 
includes ascites,  pleural effusion,  pericardial effusion,  
and skin edema [6].  In general,  HF shows poor clinical 
outcomes,  and mortality rates for this condition are 
greater than 50% [7 , 8].
The treatment strategy for HF due to DS-TAM is not 
clearly defined,  and several lethal cases have been 
reported with no treatment [3 , 9].  For cardiopulmo-
nary failure due to severe TAM,  exchange transfusion 
(ET) might be effective; however,  ET alone is not 
always curative for HF infants with TAM [3].  As an 
adjunct,  low-dose cytarabine (LD-CA) treatment is 
recommended for patients with clinical impairments 
associated with TAM,  especially high white blood cell 
(WBC) or blast counts [4 , 9 , 10].  A few reports have 
suggested that LD-CA treatment is also effective in 
infants with HF secondary to TAM [9 , 11].
In this report,  we describe three severe cases of 
TAM in infants with HF who required intensive care.  
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Most cases of transient abnormal myelopoiesis (TAM) in neonates with Down syndrome (DS) resolve sponta-
neously; however,  DS-TAM neonates with hydrops fetalis (HF) show poor clinical outcomes.  We report three 
infants with DS-TAM and HF who were treated with exchange transfusion (ET) followed by low-dose cytara-
bine (LD-CA).  All of them survived without developing liver failure,  acute leukemia,  or other serious adverse 
events.  Our results suggest that this combination treatment with ET and LD-CA would be safe,  tolerable and 
effective as an novel approach for DS-TAM patients with HF.
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All three cases were successfully treated with LD-CA 
after ET,  and all were alive after the treatments.  We 
discuss this combined therapy for HF due to DS-TAM 
and review the relevant literature.
Case Reports
Case 1. A girl was born to a 33-year-old gravida 
4 para 3 woman.  Antenatal ultrasound at 38 weeks 
detected pleural effusion,  pericardial effusion,  and 
ascites,  and she was diagnosed with HF.  On the same 
day,  the patient was delivered by cesarean section due to 
fetal distress.  Immediately after birth,  she was intu-
bated and underwent drainage of pleural and pericar-
dial effusion.  Diagnosis of trisomy 21 was made by 
G-band staining of the peripheral blood.  At birth,  the 
WBC count was 213,000/µL,  and 68.5% of the WBC 
were blast cells (Table 1).  She was diagnosed with 
persistent pulmonary hypertension of the newborn 
(PPHN),  and inhalation of nitric oxide was initiated.  
Catecholamine and hydrocortisone were also required.  
Because the patient’s respiratory and circulatory failure 
further deteriorated,  ET was performed on days 2 and 
3.  Rasburicase was administered for hyperuricemia 
(6.4 mg/dL).  The WBC count was reduced after ET on 
day 2,  but was restored on day 3.  LD-CA therapy 
(0.9 mg/kg/day) was started after ET on day 3 and 
stopped on day 8 because of pancytopenia.  Her general 
condition improved after ET and CA.  Because of pan-
cytopenia,  she needed a blood transfusion on day 26 
and administrations of granulocyte-colony stimulating 
factor (G-CSF 4 µg/kg) on days 25 and 26.  She was dis-
charged on day 48.  Currently,  she is 3 years old and has 
not developed acute myeloid leukemia or distinct liver 
dysfunction (Fig. 1).
Case 2. A girl was born to a 34-year-old gravida 
0 para 0 woman.  Antenatal ultrasound at 30 weeks 
detected hydrops (pericardial effusion,  ascites),  hep-
atomegaly,  and ventricular septal defects (VSDs).  
Hydrops did not deteriorate,  and the girl was delivered 
by cesarean section due to fetal distress at 38 weeks.  At 
birth,  she was intubated.  Diagnosis of trisomy 21 was 
made by G-band staining of the peripheral blood.  The 
WBC count was 61,380/µL,  and 46.0% of the WBC 
were blast cells.  VSD was identified.  She was diagnosed 
with PPHN; consequently,  inhalation of nitric oxide 
and continuous injection of prostaglandin I2 were initi-
ated.  Catecholamine and hydrocortisone were required.  
ET was performed on days 1 and 2.  Because of the per-
sistence of disseminated intravascular coagulation,  
LD-CA therapy (0.9 mg/kg/day) was started on day 3 
and continued for 7 days.  After the combination ther-
apy,  her respiratory distress and circulatory failure 
gradually improved.  She received G-CSF (4 µg/kg) on 
day 28 and repeated blood transfusion because of pan-
cytopenia.  Aminotransferase (AST) (peak 373 IU/L on 
day 20),  alanine aminotransferase (ALT) (peak 
437 IU/L on day 20),  and direct bilirubin (peak 
4.6 mg/dL on day 26) levels were elevated starting from 
the 2 nd week of her life,  but they decreased gradually 
and finally returned to the normal range on day 70.  
Pulmonary artery banding was performed on day 121,  
and she was discharged in the 4 th month of her life.  
Currently,  she is 2 years and 9 months old,  and has not 
developed acute myeloid leukemia or distinct liver dys-
function (Fig. 2).
Case 3. A boy was born to a 33-year-old gravida 
2 para 2 woman.  Prenatal ultrasound at 33 weeks 
detected fetal hepatosplenomegaly,  cardiomegaly,  and 
fetal pericardial effusion.  He was delivered by cesarean 
section the next day.  At birth,  he was intubated.  
Trisomy 21 was detected by G-band staining of the 
peripheral blood.  The WBC count was 237,420/µL,  
and 55.0% of the WBC were blast cells.  He was diag-
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Table 1　 Clinical and laboratory ﬁndings at birth in three cases
Case Male/Female
gestational
age (week)
birth
weight (g)
APGAR
score Karyotype
WBC
(×106/ml)
Blast
(%)
Hgb
(g/dl)
Plt
(×106/ml)
LDH
(U/l)
AST
(U/l)
ALT
(U/l)
1 Female 38 2,717 2/5 47, XX, ＋21 213 68.5 14.6 149 2,442  52 22
2 Female 38 2,932 4/8 47, XX, ＋21 61.4 46.0 14.1 224 1,207  47 78
3 Male 33 2,651 3/6 47, XY, ＋21 237.4 55.0 11.6 147 6,048 148 363
WBC,  white blood cell count; Hgb,  hemoglobine; Plt,  platelet; LDH,  lactate dehydrogenase; AST,  aspartate transaminase; ALT,  ala-
nine transaminase.
nosed with PPHN,  and inhalation of nitric oxide ther-
apy was initiated.  Catecholamine and hydrocortisone 
were required.  ET was performed on day 1.  Because of 
the elevation of AST and ALT,  LD-CA therapy (0.5 mg/
kg/day) was initiated on day 3 and performed for 7 
days.  His general condition improved after ET and CA.  
Rasburicase was administered because his serum uric 
acid level was elevated (11.3 mg/dL) before starting 
chemotherapy.  AST (peak 169 U/L on day 22),  ALT 
(peak 117 IU/L on day 22),  and direct bilirubin (peak 
6.3 mg/dL on day 18) levels were elevated starting from 
the 2 nd week of his life,  but they decreased gradually 
and returned to the normal range at 6 months of age.  
He received G-CSF (4 µg/kg) on day 30 and blood 
transfusions on days 20 and 25 because of pancytope-
nia.  He was discharged on day 47.  Currently,  he is 1 
year and 4 months old and has not developed AML or 
distinct liver dysfunction (Fig. 3).
Written informed consent was obtained from each 
parent before beginning treatment.
Literature Review
We reviewed Japanese and English case reports from 
Ichushi Web and Pubmed using key words TAM,  HF 
and systemic edema.  Reports with no records of treat-
ment were excluded.  A total of 25 (9 Japanese and 16 
English [3 , 9 , 11-17]) DS-TAM cases with HF were 
reported from 2002 to 2016 (Table 2).  There was no 
differences in the overall survival among the different 
treatment protocols (Table 3).
Discussion
Blast cells start to proliferate in the liver and spleen 
in utero,  in a process known as extramedullary hemato-
poiesis,  and shift to the bone marrow after birth [18].  
The cases of patients with severe TAM are often compli-
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Fig. 1　 (A) Clinical course of case 1.  NO,  inhalation of nitric oxide; PSL,  prednisolone; ET,  exchange transfusion; G-CSF,  
granulocyte-colony stimulating factor; WBC,  white blood cell; D-bil,  direct bilirubin.  (B) Relation of WBC,  AST,  and therapies.
cated by fetal death,  hydrops,  and liver failure in utero.  
Hydrops is a manifestation related to poor clinical out-
comes [4 , 5].  Klusmann et al.  reported that the early 
death rate of TAM babies with hydrops is 71% (5 out of 
7 patients) with any treatment [4].
Recent reports indicate that ET is effective in con-
trolling cardiopulmonary failure accompanied by 
hydrops in DS-TAM [4 , 17] because pulmonary hyper-
tension in TAM patients is presumably caused by 
hyperviscosity and embolism of blast cells [17].  Indeed,  
obvious reduction of the blast cells by ET results in the 
improvement of pulmonary hypertension [17].  
In the present cases,  ET markedly decreased the 
number of blast cells and prevented respiratory and cir-
culatory failure.  Several studies have suggested that 
cytokines produced by blast cells contribute to the 
pathogenesis of TAM [2 , 19-21].  Our previous study 
revealed that abnormal cytokinemia might play an 
important role in the pathophysiology of TAM [22].  
Shitara reported that the abnormal production of cyto-
kines such as interleukin (IL)-6,  IL-8,  and IL-13 was 
related to TAM and pericardial effusion [21].  Hattori et 
al.  reported that TGF-β was strongly associated with 
liver fibrosis [20].  Therefore,  reducing the number of 
blast cells and the serum levels of inflammatory cyto-
kines by ET would presumably improve the pathological 
conditions in patients.
The LD-CA treatment has been highly effective in 
several severe DS-TAM cases.  The Japanese Pediatric 
Leukemia/Lymphoma Study Group (JPLSG) recom-
mends that TAM patients who have WBC counts of 
over 100,000/µL receive LD-CA treatment.  JPLSG also 
recommends that infants with WBC counts < 100,000/
µL be treated with LD-CA if they present with symp-
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Fig. 2　 (A) Clinical course of case 2.  NO,  inhalation of nitric oxide; PSL,  prednisolone; PGI2,  prostaglandin I2; hANP,  
carperitide; ET,  exchange transfusion; G-CSF,  granulocyte-colony stimulating factor; WBC,  white blood cell; D-bil,  direct bilirubin.  (B) 
Relation of WBC,  AST,  and therapies.
toms related to poor outcomes such as elevated direct 
bilirubin,  effusions (pleural,  peritoneal,  or pericardi-
nal),  and systemic edema [23].  The German BFM 
group reported the following patient data in TAM 
patients who were treated with 0.5-1.5 mg/kg LD-CA 
for 3-12 days: WBC count > 50,000/µL,  platelet count 
< 100,000/µL,  cholestasis (direct bilirubin > 15 mg/dL),  
and deterioration of the general condition due to liver 
failure [4].  There are no defined criteria for initiating 
LD-CA treatment; therefore,  it is difficult to determine 
when chemotherapy should be initiated in critically ill 
patients without an increase in WBC counts.  WBC 
counts do not always correlate with the severity of TAM,  
and a few reports have described patients with poor 
outcomes whose WBC counts were < 100,000/µL [9].
Moreover,  it was likely that ET successfully removed 
blast cells and abnormal cytokines; if so,  however,  the 
effect was transient,  and ET could not completely 
eliminate the residual blasts.  Therefore,  a sustained 
immune attack could cause liver failure.  TAM blasts 
start to proliferate in utero,  and thus a few severe TAM 
cases with HF are lethal at birth [1].  Moreover,  irre-
versible liver fibrosis could develop due to sustained 
abnormal cytokinemia with or without TAM blasts 
[3 , 20].  Therefore,  the timing of ET and LD-CA is also 
important,  and they should be performed in the early 
period,  because a few reports have shown that patients 
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Table 2　 Therapies and survival rates in previous reports
Therapy Number of case
Number of 
survivor
Survival 
rate
no therapy or steroid alone 10 3 30%
LD-CA without ET 4 3 75%
ET without LD-CA 6 2 33%
combine therapy 5 2 40%
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Fig. 3　 (A) Clinical course of case 3.  NO,  inhalation of nitric oxide; HDC,  hydrocortisone; ET,  exchange transfusion; G-CSF,  
granulocyte-colony stimulating factor; WBC,  white blood cell; D-bil,  direct bilirubin.  (B) Relation of WBC,  AST,  and therapies.
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Table 3　  
No. Ref Symptom Preterm WBC Therapy Outcomeor term (×106/ml) ET CA Steroid
1 9 SE PlE PeE term 231 〇 〇 Died
2 9 Hydrops preterm  57 Died 48 h
3 11 Hydrops preterm  13 〇 Alive
4 11 Hydrops preterm  16 〇 Alive
5 12 SE PeE As preterm  57 Died at day 16
6 13 Hydrops preterm  77 Alive
7 14 Hydrops preterm Died 11 min
8 15 Hydrops preterm 221 〇 Alive
9 16 SE PeE As term 287 〇 〇 Died 2 months
10 3 SE preterm  21 Died at day 1
11 3 SE term  13 〇 〇 〇 Alive
12 3 SE preterm  26 Died 
13 3 SE preterm 114 〇 Died at day 44
14 3 SE preterm  46 〇 〇 Died at day 55
15 17 SE PlE PeE preterm 143 〇 〇 Alive
16 17 PlE PeE As preterm 165 〇 Died at day 5
17 J1 Hydrops preterm 232 〇 Died at day 37
18 J2 Hydrops term 139 〇 Died at day 16
19 J3 Hydrops preterm 342 Died at day 15
20 J4 Hydrops preterm 146 〇 Alive
21 J4 Hydrops preterm 144 〇 〇 Died at day 14
22 J4 Hydrops preterm  45 〇 〇 Died at day 37
23 J4 Hydrops preterm 144 〇 〇 〇 Alive
24 J5 Hydrops preterm  34 〇 〇 Alive
25 J6 SE As preterm  42 〇 Alive
26 　 Hydrops term 213 〇 〇 〇 Alive
27 　 Hydrops term  61 〇 〇 〇 Alive
28 　 Hydrops preterm 237 〇 〇 〇 Alive
Case 17-25 are from reports written in Japanese.  Reference of J1-J6 shown below.  Case 26-28 are present cases.  Ref,  reference;  
SE,  systemic edema; PlE,  pleural eﬀusion; PeE,  pericardial eﬀusion; As,  ascites.
J1) Imai K,  Toyoshima K,  Kotani M,  Nagasawa M,  Shibasaki J,  Hoshino R,  Ohyama M,  Kawataki M and Y Itani: The pathological exam-
inations of liver specimens of three infants with transient abnormal myelopoiesis (TAM) accompanying hepatic ﬁbrosis.  Jornal of Japan 
Society for Premature and Newborn medicine (2010) 22: 70-76 (in Japanese).
J2) Aiba K,  Sugiura T,  Ninchoji T,  Nomura T,  Kouwaki M and Koyama N: Transient abnormal myelopoiesis with pseudohyperkalemia 
cause by extreme leukocytosis: a case report.  J Jpn Pediatr Soc (2010) 114: 515-518 (in Japanese).
J3) Mashiyama F,  Imamura T,  Satou M,  Maeda H,  Kanai Y,  Ogasawara K,  Haneda K,  Honda Y and Ohto H: A severe case of transient 
abnormal myelopoiesis in Down syndrome with hydrops fetalis.  Jpn J Obstet Gynecol Neonatal Hematol (2014) 24: 22-23 (in Japanese).
J4) Ohzeki K,  Iida A,  Matsui S,  Okabashi A,  Shimamura N,  Ogino H,  Okada M,  Kouge A,  Oohashi S,  Fujinaka Y,  Masunaga K and 
Takigawa I: Four cases of premature infants with Down syndrome who presented with TAM and antenatally identiﬁed hydrops fetalis.  J Jpn 
Soc Perin Neon Med (2014) 50: 1104-1109 (in Japanese).
J5) Suenaga H,  Uchiyama A,  Okamura T,  Ohno H,  Sugita E,  Imai K,  Masumoto K,  Titsu S,  Nakanishi H and Kusuda S: Eﬃcacy of 
Rasburicase for the treatment of hyperuricemia due to transient abnormal myelopoiesis in a preterm infant with Down syndrome.  Journal of 
Japan Society for neonatal health and development (2016) 28: 67-71 (in Japanese).
J6) Nakayama M,  Matsushima M,  Fukagawa Y,  Kaneda Y,  Tanaka K,  Yamada K,  Izawa T,  Furukawa S,  Kobayashi Y and Iwashita M:  
A case of transient abnormal myelopoiesis with hydrops.  Tokyo J Ob-Gyn (2016) 65: 547-551 (in Japanese).
died due to liver failure at 1-2 months after birth even if 
their symptoms temporarily improved as a result of ET 
after birth [2].  Thus,  the results of our study suggest 
that the combination of ET followed by LD-CA in the 
early period after birth might be safe and might prevent 
the development of liver failure.  Further studies with 
larger samples are needed to verify these results.
When administering LD-CA treatment to infants 
with severe TAM,  it is important to consider the poten-
tial side effects.  Even though LD-CA treatment can 
sometimes cause myelosuppression (anemia,  thrombo-
cytopenia,  and leukopenia) and tumor lysis syndrome 
(renal dysfunction,  electrolyte disturbance,  and hyper-
uricemia),  only a few reports have demonstrated that 
LD-CA treatment followed by ET rescued patients,  
even in cases with hydrops [11].  In the present three 
cases,  blood transfusion was required to treat anemia 
and thrombopenia and G-CSF to treat leukopenia.  
G-CSF administration in older patients with myelodys-
plastic syndrome occasionally increases the number of 
blast cells [24].  Indeed,  G-CSF administration in TAM 
patients could increase blast cells and accelerate leuke-
mogenesis.  In the present cases,  the number of blast 
cells did not increase,  and AML did not occur; how-
ever,  a shorter period of LD-CA therapy may have 
reduced the risk of leukopenia.  The optimal treatment 
period should be investigated in future studies.  In addi-
tion,  none of our 3 present cases were complicated with 
tumor lysis syndrome.  Hayasaka et al.  [17] reported that 
ET may reduce the risk of tumor lysis syndrome by 
decreasing the number of blast cells.  Our cases also 
indicated that ET could be a suitable pretreatment for 
chemotherapy to avoid tumor lysis syndrome.
Liver fibrosis is one of the most severe complications 
of TAM.  Previous reports suggest that inflammatory 
cytokines produced by megakaryoblasts in the liver,  
such as TGF-β1 and platelet-derived growth factor,  
promote liver fibrosis by facilitating the synthesis of 
extracellular matrix [2 , 19 , 20].  In the present study,  
cases 2 and 3 had liver dysfunction,  but it improved 
with supportive therapy.  Moreover,  all 3 patients sur-
vived without lethal liver failure.  Thus,  it is possible 
that LD-CA with ET prevents the progression of lethal 
liver fibrosis by reducing the number of blast cells,  
which produce inflammatory cytokines.
In conclusion,  our 3 patients with hydrops and 
severe TAM were rescued from respiratory and circula-
tory failure by reducing their numbers of blast cells 
using a safe combination therapy of ET and LD-CA.  
Further large-scale studies will be needed to clarify the 
efficacy of LD-CA after ET therapy.
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